SAB Biotherapeutics (NASDAQ:SABS) Rating Increased to Strong-Buy at Jefferies Financial Group

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by Jefferies Financial Group to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

A number of other equities analysts also recently issued reports on the company. Rodman & Renshaw reiterated a “buy” rating and issued a $13.00 price objective on shares of SAB Biotherapeutics in a report on Monday, May 11th. Weiss Ratings reiterated a “sell (d+)” rating on shares of SAB Biotherapeutics in a report on Friday, April 10th. Wall Street Zen downgraded SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Zacks Research upgraded SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Finally, HC Wainwright increased their price objective on SAB Biotherapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $11.00.

SAB Biotherapeutics Price Performance

SABS opened at $3.68 on Wednesday. The stock has a fifty day simple moving average of $3.85 and a two-hundred day simple moving average of $3.84. The company has a current ratio of 11.45, a quick ratio of 11.45 and a debt-to-equity ratio of 0.01. The company has a market cap of $187.50 million, a price-to-earnings ratio of -1.74 and a beta of 0.55. SAB Biotherapeutics has a 12-month low of $1.60 and a 12-month high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). Research analysts predict that SAB Biotherapeutics will post -1.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SAB Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Commodore Capital LP bought a new stake in SAB Biotherapeutics in the 3rd quarter worth about $8,847,000. Stempoint Capital LP increased its holdings in SAB Biotherapeutics by 155.9% in the 1st quarter. Stempoint Capital LP now owns 375,000 shares of the company’s stock worth $1,436,000 after buying an additional 228,442 shares in the last quarter. Affinity Asset Advisors LLC bought a new stake in SAB Biotherapeutics in the 1st quarter worth about $2,202,000. Monashee Investment Management LLC bought a new stake in SAB Biotherapeutics in the 1st quarter worth about $1,915,000. Finally, PNC Financial Services Group Inc. bought a new stake in SAB Biotherapeutics in the 1st quarter worth about $29,000. 7.82% of the stock is currently owned by institutional investors.

Key SAB Biotherapeutics News

Here are the key news stories impacting SAB Biotherapeutics this week:

• Positive Sentiment: Jefferies initiated coverage of SAB Biotherapeutics with a Buy rating, a bullish signal that may be encouraging traders to revalue the stock higher. Jefferies initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation
• Neutral Sentiment: Brookline Capital Markets released updated earnings estimates across 2026-2030, projecting continued losses in the near term but a path to profitability by FY2030. These forecasts provide a longer-term valuation framework, but they do not appear to be a major immediate catalyst. SAB Biotherapeutics Inc SABS
• Negative Sentiment: The company’s most recent quarterly results missed analyst expectations, with EPS of -$0.35 versus consensus of -$0.20, reinforcing concerns about near-term execution and profitability. SAB Biotherapeutics Inc SABS

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.